About the Event
Using its AI and supercomputer-powered platform, Gain Therapeutics (NASDAQ: GANX) has developed GT-02287, a disease-modifying small molecule therapy for Parkinson’s disease patients harboring a mutation of the GBA1 gene.
Join our webinar with Matthias Alder, Gain CEO, to learn more and find out why Gain has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research and other private and public foundations.